Biosion and Bonita Biotech (ACRS) disclose 9.4% Aclaris ownership via 13G/A

Rhea-AI Filing Summary

Biosion, Inc. and its wholly owned subsidiary Bonita Biotech (HK) Limited report their ownership of Aclaris Therapeutics, Inc. common stock on an amended Schedule 13G. Bonita Biotech (HK) Limited holds 11,281,950 shares of common stock, representing 9.4% of the class, with sole voting and dispositive power.

The filing explains that a warrant originally held by Biosion, Inc. for 11,281,985 shares was assigned to Bonita Biotech (HK) Limited on December 9, 2025 and then exercised on a cashless basis, resulting in issuance of 11,281,950 shares on December 15, 2025. The 9.4% figure is based on 119,624,542 shares of Aclaris common stock, which includes 108,342,592 shares outstanding as referenced in a prior Form 8-K and the new shares issued to Bonita Biotech (HK) Limited. The reporting persons certify the shares are not held to change or influence control of Aclaris.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

Aclaris Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.00001 par value

(Title of Class of Securities)

00461U105

(CUSIP Number)

12/09/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

Biosion, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CHINA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,281,950.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,281,950.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,281,950.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) Pursuant to the Schedule 13G filed by Biosion, Inc. on November 25, 2024, there were 11,281,985 shares of Common Stock issuable to Biosion, Inc. upon exercise of the Issuer warrant held by it. Biosion, Inc. assigned the Issuer warrant to its wholly-owned subsidiary, Bonita Biotech (HK) Limited on December 9, 2025, followed by the exercise of the Issuer warrant by Bonita Biotech (HK) Limited by way of cashless exercise in accordance with the terms thereof on December 9, 2025, which resulted in Bonita Biotech (HK) Limited being issued 11,281,950 shares of Common Stock on December 15, 2025. (2) Based on 119,624,542 shares of Common Stock of the Issuer, including (i) 108,342,592 shares of Common Stock outstanding as disclosed in the Issuer's current report on Form 8-K filed with the SEC on November 6, 2025, and (ii) 11,281,950 shares of Common Stock issued to Bonita Biotech (HK) Limited upon exercise of the Issuer warrant held by it.

SCHEDULE 13G

CUSIP No. 00461U105

1

Names of Reporting Persons

Bonita Biotech (HK) Ltd

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

HONG KONG

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 11,281,950.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 11,281,950.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

11,281,950.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.4 %

12

Type of Reporting Person (See Instructions)

CO

Comment for Type of Reporting Person: (1) Pursuant to the Schedule 13G filed by Biosion, Inc. on November 25, 2024, there were 11,281,985 shares of Common Stock issuable to Biosion, Inc. upon exercise of the Issuer warrant held by it. Biosion, Inc. assigned the Issuer warrant to its wholly-owned subsidiary, Bonita Biotech (HK) Limited on December 9, 2025, followed by the exercise of the Issuer warrant by Bonita Biotech (HK) Limited by way of cashless exercise in accordance with the terms thereof on December 9, 2025, which resulted in Bonita Biotech (HK) Limited being issued 11,281,950 shares of Common Stock on December 15, 2025. (2) Based on 119,624,542 shares of Common Stock of the Issuer, including (i) 108,342,592 shares of Common Stock outstanding as disclosed in the Issuer's current report on Form 8-K filed with the SEC on November 6, 2025, and (ii) 11,281,950 shares of Common Stock issued to Bonita Biotech (HK) Limited upon exercise of the Issuer warrant held by it.

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Aclaris Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 701 Lee Road, Suite 103, Wayne, Pennsylvania, 19087
Item 2.
(a)	Name of person filing: 1. Biosion, Inc. 2. Bonita Biotech (HK) Limited
(b)	Address or principal business office or, if none, residence: For all reporting persons: 5th Floor, Building D 3-1 Zhongdan Unit, South Longshan Rd Jiangbei New District Nanjing, Jiangsu, China
(c)	Citizenship: Biosion, Inc. is established under the laws of the People's Republic of China. Bonita Biotech (HK) Limited is incorporated under the laws of Hong Kong.
(d)	Title of class of securities: Common Stock, $0.00001 par value
(e)	CUSIP No.: 00461U105
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information for each reporting person contained in Items 5-9 of the cover pages is incorporated herein by reference.
(b)	Percent of class: The information for each reporting person contained in Item 11 of the cover pages is incorporated herein by reference.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: The information for each reporting person contained in Item 5 of the cover pages is incorporated herein by reference.
	(ii) Shared power to vote or to direct the vote: The information for each reporting person contained in Item 6 of the cover pages is incorporated herein by reference.
	(iii) Sole power to dispose or to direct the disposition of: The information for each reporting person contained in Item 7 of the cover pages is incorporated herein by reference.
	(iv) Shared power to dispose or to direct the disposition of: The information for each reporting person contained in Item 8 of the cover pages is incorporated herein by reference.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Biosion, Inc.

Signature:	/s/ MINGJIU CHEN
Name/Title:	MINGJIU CHEN / CEO
Date:	01/09/2026

Bonita Biotech (HK) Ltd

Signature:	/s/ MINGJIU CHEN
Name/Title:	MINGJIU CHEN / Director
Date:	01/09/2026

Exhibit Information

Exhibit 99.1 Joint Filing Agreement

FAQ

How many Aclaris Therapeutics (ACRS) shares do Biosion and Bonita Biotech report owning?

The reporting persons state that Bonita Biotech (HK) Limited beneficially owns 11,281,950 shares of Aclaris Therapeutics common stock, with sole voting and dispositive power over those shares.

What percentage of Aclaris Therapeutics (ACRS) does Biosion and Bonita Biotech own according to this Schedule 13G/A?

The filing reports that the 11,281,950 shares beneficially owned represent 9.4% of Aclaris Therapeutics’ outstanding common stock.

How did Bonita Biotech (HK) Limited acquire its Aclaris Therapeutics (ACRS) shares?

The document explains that a warrant held by Biosion, Inc. for 11,281,985 shares of Aclaris common stock was assigned to Bonita Biotech (HK) Limited on December 9, 2025 and then exercised by Bonita via cashless exercise, resulting in issuance of 11,281,950 shares on December 15, 2025.

What total share count is used to calculate the 9.4% ownership in Aclaris Therapeutics (ACRS)?

The 9.4% ownership is based on 119,624,542 shares of Aclaris common stock, including 108,342,592 shares outstanding cited in a November 6, 2025 Form 8-K and 11,281,950 shares issued to Bonita Biotech (HK) Limited upon warrant exercise.

Do Biosion and Bonita Biotech indicate an intent to influence control of Aclaris Therapeutics (ACRS)?

The certification states that the securities were not acquired and are not held for the purpose of changing or influencing control of Aclaris Therapeutics and are not held in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.

Who signed the Aclaris Therapeutics (ACRS) Schedule 13G/A on behalf of the reporting persons?

The filing is signed by MINGJIU CHEN, identified as CEO for one signature block and as Director for another, each dated January 9, 2026.